Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas

Hepatology

Volumn 44, Issue 4, 2006, Pages 1012-1024

  Luo, Jian Hua ^a   Ren, Baoguo ^a   Keryanov, Sergei ^a   Tseng, George C ^b   Rao, Uma N M ^a   Monga, Satdarshan P ^a   Strom, Steven ^a   Demetris, Anthony J ^a   Nalesnik, Michael ^a   Yu, Yan P ^a   Ranganathan, Sarangarajan ^a   Michalopoulos, George K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; FICOLIN; GLYPICAN 3; LIVER PROTEIN; OSTEOPONTIN; PROTEIN DLK1; PROTEIN EDIL3; PROTEIN MALAT1; PROTEIN PEG10; PROTEIN SPONDIN 2; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BONE GROWTH FACTORS; CARRIER PROTEIN; DLK1 PROTEIN, HUMAN; EDIL3 PROTEIN, HUMAN; FCN3 PROTEIN, HUMAN; GLYCOPROTEIN; GLYPICAN; LECTIN; MEMBRANE PROTEIN; PEG10 PROTEIN, HUMAN; PREADIPOCYTE FACTOR 1; PROTEIN; PROTEOHEPARAN SULFATE; REPRESSOR PROTEIN; SIALOGLYCOPROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPP1 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; GENOMIC INSTABILITY; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CLUSTER ANALYSIS; COMPARATIVE STUDY; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOME; LIVER TUMOR; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CLUSTER ANALYSIS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; GLYCOPROTEINS; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; HEPATOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS; LIVER NEOPLASMS; MEMBRANE PROTEINS; OSTEOPONTIN; PROTEINS; REPRESSOR PROTEINS; SIALOGLYCOPROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33750613935     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21328     Document Type: Article

References (40)

1. Lee JS, Thorgeirsson SS. Genetic profiling of human hepatocellular carcinoma. Semin Liver Dis 2005;25:125-132.
2. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004;127:S51-S55.
3. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. HEPATOLOGY 2004;40:667-676.
4. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
5. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. HEPATOLOGY 2005:42:809-818.
6. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811-818.
7. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14:848-862.
8. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
9. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003;94:259-262.
10. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
11. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
12. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-6254.
13. Selleck SB. Shedding light on the distinct functions of proteoglycans. Sci STKE 2006;2006:pe17.
14. Ono R, Kobayashi S, Wagatsuma H, Aisaka K, Kohda T, Kaneko-Ishino T, Ishino F. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 2001;73:232-237.
15. Tsou AP, Chuang YC, Su JY, Yang CW, Liao YL, Liu WK, Chiu JH, et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci 2003;10: 625-635.
16. Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, Yamaoka Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 2003;63:3043-3048.
17. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005;9:235-251, vi.
18. Rezaee M, Penta K, Quertermous T. Dell mediates VSMC adhesion, migration, and proliferation through interaction with integrin alpha-(v)beta(3). Am J Physiol Heart Circ Physiol 2002;282:H1924-H1932.
19. Aoki M, Kanamori M, Ohmori K, Takaishi M, Huh NH, Nogami S, Kimura T. Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF. Biochem Biophys Res Commun 2005;333:990-995.
20. Hirohashi K, Yamamoto T, Uenishi T, Ogawa M, Sakabe K, Takemura S, Shuto T, et al. CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology 2004;51:1121-1123.
21. Iso Y, Sawada T, Okada T, Kubota K. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma. J Surg Oncol 2005;92:304-311.
22. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52: 19-24.
23. Akaiwa M, Yae Y, Sugimoto R, Suzuki SO, Iwaki T, Izuhara K, Hamasaki N. Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. J Histochem Cytochem 1999;47:777-786.
24. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, et al. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem 1998;273:20721-20727.
25. Sorensen R, Thiel S, Jensenius JC. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol 2005;27:299-319.
26. Bjornsson HT, Cui H, Gius D, Fallin MD, Feinberg AP. The new field of epigenomics: implications for cancer and other common disease research. Cold Spring Harb Symp Quant Biol 2004;69:447-456.
27. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
28. Carraway KL, 3rd, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994;269:14303-14306.
29. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995;11:221-229.
30. Prawitt D, Enklaar T, Gartner-Rupprecht B, Spangenberg C, Lausch E, Reutzel D, Fees S, et al. Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor. Nat Genet 2005;37:785-786; author reply 786-787.
31. Xu D, Makkinje A, Kyriakis JM. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J Biol Chem 2005;280:2924-2933.
32. Pante G, Thompson J, Lamballe F, Iwata T, Ferby I, Barr FA, Davies AM, et al. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol 2005;171:337-348.
33. Kobayashi S, Wagatsuma H, Ono R, Ichikawa H, Yamazaki M, Tashito H, Aisaka K, et al. Mouse Peg9/Dlk1 and human PEG9/DLK1 are paternally expressed imprinted genes closely located to the maternally expressed imprinted genes: mouse Meg.3/Gtl2 and human MEG3. Genes Cells 2000; 5:1029-1037.
34. Schmidt JV, Matteson PG, Jones BK, Guan XJ, Tilghman SM. The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. Genes Dev 2000; 14:1997-2002.
35. Baladron V, Ruiz-Hidalgo MJ, Nueda ML, Diaz-Guerra MJ, Garcia-Ramirez JJ, Bonvini E, Gubina E, et al. dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats. Exp Cell Res 2005;303:343-359.
36. Baladron V, Ruiz-Hidalgo MJ, Bonvini E, Gubina E, Notario V, Laborda J. The EGF-like homeotic protein dlk affects cell growth and interacts with growth-modulating molecules in the yeast two-hybrid system. Biochem Biophys Res Commun 2002;291:193-204.
37. Jensen CH, Jauho EI, Santoni-Rugiu E, Holmskov U, Teisner B, Tygstrup N, Bisgaard HC. Transit-amplifying ductular (oval) cells and their hepatocytic progeny are characterized by a novel and distinctive expression of delta-like protein/preadipocyte factor 1/fetal antigen 1. Am J Pathol 2004; 164:1347-1359.
38. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002;13:419-424.
39. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sugano Y, Yamashiki N, et al. Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth. HEPATOLOGY 2000;32:218-227.
40. Roberts AB, McCune BK, Spotn MB. TGF-beta: regulation of extracellular matrix. Kidney Int 1992;41:557-559.